A clinicobiological model predicting survival in medulloblastoma

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7613-7620

  Ray, Amit ^a,b   Ho, Michael ^a   Ma, Jing ^a   Parkes, Robert K ^c   Mainprize, Todd G ^a   Ueda, Shigeo ^a   McLaughlin, John ^c   Bouffet, Eric ^a   Rutka, James T ^a   Hawkins, Cynthia E ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CANCER MODEL; CANCER SURVIVAL; CHILD; FEMALE; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

ADOLESCENT; APOPTOSIS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INFANT; KI-67 ANTIGEN; MALE; MEDULLOBLASTOMA; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; RECEPTOR, TRKC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9344240453     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0499     Document Type: Article

References (43)

1. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (Lond) 2002;415:436-42.
2. Goussia AC, Bruner JM, Kyritsis AP, Agnantis NJ, Fuller GN. Cytogenetic and molecular genetic abnormalities in primitive neuroectodermal tumors of the central nervous system. Anticancer Res 2000;20:65-73.
3. Badiali M, Pession A, Basso G, et al. N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori 1991;77:118-21.
4. Batra SK, McLendon RE, Koo JS, et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995;24:39-45.
5. Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 1990;50:2347-50.
6. Bruggers CS, Tai KF, Murdock T, et al. Expression of the c-Myc protein in childhood medulloblastoma. J Pediatr Hematol Oncol 1998;20:18-25.
7. DeChiara C, Borghese A, Fiorillo A, et al. Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. Detection of a novel chromosomal abnormality. Childs Nerv Syst 2002;18:380-4.
8. Korshunov A, Savostikova M, Ozerov S. Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression. J Neurooncol 2002;58:271-9.
9. Liu Y, Mao B, Hokeung N, Chen Y, Gao L. Expression of C-myc and N-myc protein in adulthood and childhood medulloblastomas and prognostic analysis [in Chinese]. Hua Xi Yi Ke Da Xue Xue Bao 2001;32:120-2.
10. Herms J, Neidt I, Luscher B, et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000;89:395-402.
11. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425-33.
12. Grotzer MA, Janss AJ, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000;18:1027-35.
13. Grotzer MA, Janss AJ, Phillips PC, Trojanowski JQ. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Pädiatr 2000;212:196-9.
14. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-93.
15. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer (Phila) 1999;86:364-72.
16. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Investig 2001;81:1331-8.
17. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657-62.
18. Eberhart CG, Kaufman WE, Tihan T, Burger PC. Apoptosis, neuronal maturation, and neurotrophin expression within medulloblastoma nodules. J Neuropathol Exp Neurol 2001;60:462-9.
19. Knowles RB, Kosik KS. Neurotrophin-3 signals redistribute RNA in neurons. Proc Natl Acad Sci USA 1997;94:14804-8.
20. Pello JM, Guate JL, Naves FJ, Escaf S, Vega JA. Neurotrophins and neurotrophin receptors in some neural crest-derived tumours (ganglioneuroma, phaeochromocytoma and paraganglioma). Histopathology 1999;34:216-25.
21. Grotzer MA, Geoerger B, Janss AJ, et al. Prognostic significance of Ki-67 (MIB-1) proliferation index in childhood primitive neuroectodermal tumors of the central nervous system. Med Pediatr Oncol 2001;36:268-73.
22. R Development Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2003.
23. Therneau TM GP, Pankratz VS. Penalized survival models and frailty. J Computational Graphical Statistics, 2003;12:156-75.
24. Gilbertson RJ, Pearson AD, Perry RH, Jaros E, Kelly PJ. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995;71:473-7.
25. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-45.
26. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002;126:540-4.
27. Biegel JA, Fogelgren B, Zhou JY, et al. Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system. Clin Cancer Res 2000;6:2759-63.
28. Brown HG, Kepner JL, Perlman EJ, et al. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000;59:857-65.
29. Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas. Brain Pathol 2003;13:376-85.
30. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002;28:257-82.
31. Frank AJ, Hernan R, Hollander A, et al. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res Mol Brain Res 2004;121:137-40.
32. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002;346:420-7.
33. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998;12:2973-83.
34. Quinn DI, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 2000;60:1585-94.
35. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36-44.
36. MacGregor DN, Ziff EB. Elevated c-myc expression in childhood medulloblastomas. Pediatr Res 1990;28:63-8.
37. Herms JW, Behnke J, Bergmann M, et al. Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 1997;19:510-5.
38. Haslam RH, Lamborn KR, Becker LE, Israel MA. Tumor cell apoptosis present at diagnosis may predict treatment outcome for patients with medulloblastoma. J Pediatr Hematol Oncol 1998;20:520-7.
39. Grotzer MA, Janss AJ, Fung KM, et al. Abundance of apoptotic neoplastic cells in diagnostic biopsy samples is not a prognostic factor in childhood primitive neuroectodermal tumors of the central nervous system. J Pediatr Hematol Oncol 2001;23:25-9.
40. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer (Phila) 2002;94:552-60.
41. Miralbell R, Tolnay M, Bieri S, et al. Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neurooncol 1999;45:103-10.
42. Park PC, Taylor MD, Mainprize TG, et al. Transcriptional profiling of medulloblastoma in children. J Neurosurg 2003;99:534-41.
43. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001;85:705-12.